Overview
UK-based psychedelic drug development company advancing novel ketamine and esketamine analogs for treatment-resistant depression and other psychiatric conditions. They focus on improving upon existing approved psychedelic medicines with next-generation compounds.
More in Psychedelics
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
🍄 Psychedelics
Location
London, United Kingdom
Funding
Seed · $7M
Website
clerkenwelllabs.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →